➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Baxter
McKinsey
AstraZeneca
Express Scripts

Last Updated: January 15, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205435

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 205435 describes SIVEXTRO, which is a drug marketed by Cubist Pharms Llc and is included in two NDAs. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the SIVEXTRO profile page.

The generic ingredient in SIVEXTRO is tedizolid phosphate. One supplier is listed for this compound. Additional details are available on the tedizolid phosphate profile page.
Summary for 205435
Tradename:SIVEXTRO
Applicant:Cubist Pharms Llc
Ingredient:tedizolid phosphate
Patents:7
Generic Entry Opportunity Date for 205435
Generic Entry Date for 205435*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 205435
Suppliers and Packaging for NDA: 205435
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SIVEXTRO tedizolid phosphate TABLET;ORAL 205435 NDA Merck Sharp & Dohme Corp. 67919-041 67919-041-01 30 TABLET, FILM COATED in 1 BOTTLE (67919-041-01)
SIVEXTRO tedizolid phosphate TABLET;ORAL 205435 NDA Merck Sharp & Dohme Corp. 67919-041 67919-041-02 1 BLISTER PACK in 1 CARTON (67919-041-02) > 6 TABLET, FILM COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength200MG
Approval Date:Jun 20, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 19, 2023
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Jun 20, 2019
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Jun 20, 2024
Regulatory Exclusivity Use:

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
Dow
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.